会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • DRIVING BODY ACCELERATION DEVICE USING ELASTICITY
    • 使用弹性驱动身体加速装置
    • WO2011062368A2
    • 2011-05-26
    • PCT/KR2010006848
    • 2010-10-07
    • CHO NAM JOON
    • CHO NAM JOON
    • F16H3/44F16H3/00
    • F16H3/74
    • A driving body acceleration device using elasticity includes an input gear, a carrier connected to the input gear, planetary gears mounted to the carrier such that each of the planetary gears is rotated about a hinge shaft, a sun gear threadedly engaged with the planetary gears while being surrounded by the planetary gears, an output shaft coupled to the center of the sun gear, a cam having a cam groove, and acceleration units, each of which has one end coupled to a corresponding one of the hinge shafts and the other end coupled to the cam groove, and each of which rotates a corresponding one of the hinge shafts such that each of the planetary gears is rotated, when the revolution angle at one end of each of the acceleration units is different from that at the other end of each of the acceleration units.
    • 使用弹性的驱动体加速装置包括输入齿轮,连接到输入齿轮的行星架,安装在载体上的行星齿轮,使得每个行星齿轮围绕铰链轴转动,太阳齿轮与行星齿轮螺纹接合,同时 被行星齿轮围绕的输出轴,耦合到太阳齿轮的中心的输出轴,具有凸轮槽的凸轮和加速单元,每个加速单元的一端联接到对应的一个铰链轴,另一端连接 并且当每个加速单元的一端的旋转角度与每个加速度单元的另一端处的旋转角度不同时,每个行星齿轮都旋转相应的一个铰链轴, 的加速单位。
    • 7. 发明申请
    • METHOD OF FABRICATING LIPID BILAYER MEMBRANES ON SOLID SUPPORTS
    • 在固体支撑物上制备脂质双层膜的方法
    • WO2006110350A2
    • 2006-10-19
    • PCT/US2006/012085
    • 2006-03-29
    • THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYCHO, Nam-JoonFRANK, Curtis, W.
    • CHO, Nam-JoonFRANK, Curtis, W.
    • C12M3/00
    • G01N33/533B82Y5/00G01N33/554Y10T428/31678
    • The present invention provides a method of producing a planar lipid bilayer on a solid support. With this method, a solution of lipid vesicles is first deposited on the solid support. Next, the lipid vesicles are destabilized by adding an amphipathic peptide solution to the lipid vesicle solution. This destabilization leads to production of a planar lipid bilayer on the solid support. The present invention also provides a supported planar lipid bilayer, where the planar lipid bilayer is made of naturally occurring lipids and the solid support is made of unmodified gold or titanium oxide. Preferably, the supported planar lipid bilayer is continuous. The planar lipid bilayer may be made of any naturally occurring lipid or mixture of lipids, including but not limited to phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, cardiolipin, cholesterol, and sphingomyelin.
    • 本发明提供了一种在固体支持物上制备平面脂双层的方法。 使用该方法,首先将脂质囊泡溶液沉积在固体支持物上。 接下来,通过向脂质囊泡溶液中加入两亲肽溶液使脂质囊泡不稳定。 这种不稳定性导致在固体支持物上产生平面脂双层。 本发明还提供了一种支撑的平面脂质双层,其中平面脂质双层由天然存在的脂质制成,并且固体支持物由未改性的金或氧化钛制成。 优选地,支撑的平面脂质双层是连续的。 平面脂质双层可以由任何天然存在的脂质或脂质混合物制成,包括但不限于磷脂酰胆碱,磷脂酰乙醇胺,磷脂酰丝氨酸,磷脂酰肌醇,心磷脂,胆固醇和鞘磷脂。
    • 8. 发明申请
    • SCREENING FOR INHIBITORS OF HCV AMPHIPATHIC HELIX (AH) FUNCTION
    • 筛选HCV双价体螺旋(AH)功能抑制剂
    • WO2010039195A3
    • 2010-05-27
    • PCT/US2009005306
    • 2009-09-23
    • UNIV LELAND STANFORD JUNIORGLENN JEFFREY SCHO NAM-JOONYANG WENJIN
    • GLENN JEFFREY SCHO NAM-JOONYANG WENJIN
    • G01N33/68G01N33/92
    • C07K14/005C12N2770/24222
    • Screening methods are provided for identifying pharmacologic inhibitors of HCV amphipathic helix (AH) function, which inhibitors are useful in the prevention and treatment of HCV infection. Also provided are compounds useful in the inhibition of viral replication. The methods of the invention are based on the unexpected discovery that the presence of an AH, e.g. an AH of an HCV polypeptide, causes an increase in the apparent diameter of the vesicles. The methods of the invention provide for addition of AH peptides to lipid vesicles, for example in a high-throughput format; which addition may be performed in the absence or presence of a candidate pharmacologic agent. The change in apparent vesicle size is measured, and compared to control samples. An increase in vesicle size or aggregation is indicative of AH function being present; and a lack of increase is indicative that the AH function is absent or has been inhibited by a test agent.
    • 筛选方法用于鉴定HCV两亲性螺旋(AH)功能的药理学抑制剂,该抑制剂可用于预防和治疗HCV感染。 还提供了用于抑制病毒复制的化合物。 本发明的方法基于意想不到的发现,即AH的存在,例如, HCV多肽的AH引起囊泡表观直径的增加。 本发明的方法例如以高通量形式向脂质囊泡中添加AH肽; 该添加可以在不存在或存在候选药剂的情况下进行。 测量表观囊泡大小的变化,并与对照样品比较。 囊泡大小或聚集的增加表明存在AH功能; 并且缺乏增加表明AH功能不存在或已被测试药剂抑制。
    • 9. 发明申请
    • SCREENING FOR INHIBITORS OF HCV AMPHIPATHIC HELIX (AH) FUNCTION
    • 筛选HCV雄性HELIX(AH)功能的抑制剂
    • WO2010039195A2
    • 2010-04-08
    • PCT/US2009/005306
    • 2009-09-23
    • THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYGLENN, Jeffrey S.CHO, Nam-JoonYANG, Wenjin
    • GLENN, Jeffrey S.CHO, Nam-JoonYANG, Wenjin
    • C12Q1/70
    • C07K14/005C12N2770/24222
    • Screening methods are provided for identifying pharmacologic inhibitors of HCV amphipathic helix (AH) function, which inhibitors are useful in the prevention and treatment of HCV infection. Also provided are compounds useful in the inhibition of viral replication. The methods of the invention are based on the unexpected discovery that the presence of an AH, e.g. an AH of an HCV polypeptide, causes an increase in the apparent diameter of the vesicles. The methods of the invention provide for addition of AH peptides to lipid vesicles, for example in a high-throughput format; which addition may be performed in the absence or presence of a candidate pharmacologic agent. The change in apparent vesicle size is measured, and compared to control samples. An increase in vesicle size or aggregation is indicative of AH function being present; and a lack of increase is indicative that the AH function is absent or has been inhibited by a test agent.
    • 提供筛选方法用于鉴定HCV两亲性螺旋(AH)功能的药理学抑制剂,该抑制剂可用于预防和治疗HCV感染。 还提供了可用于抑制病毒复制的化合物。 本发明的方法基于意想不到的发现,即AH的存在,例如, HCV多肽的AH引起囊泡表观直径的增加。 本发明的方法提供了将AH肽添加到脂质囊泡中,例如以高通量形式加入; 该添加可以在不存在或存在候选药理剂的情况下进行。 测量明显囊泡大小的变化,并与对照样品进行比较。 囊泡大小或聚集的增加表明存在AH功能; 并且缺乏增加表明AH功能不存在或已被测试者抑制。